



PointClickCare®

Titration order template guide

Table of contents



Important information about the AUSTEDO XR Pharmacy Order Template



Accessing the AUSTEDO XR Pharmacy Order Template



Finalizing the AUSTEDO XR Pharmacy Order

INDICATIONS AND USAGE

AUSTEDO XR® and AUSTEDO® are indicated in adults for the treatment of chorea associated with Huntington's disease (HD) and for the treatment of tardive dyskinesia (TD).

IMPORTANT SAFETY INFORMATION

Depression and Suicidality in Patients with Huntington's Disease: AUSTEDO XR and AUSTEDO can increase the risk of depression and suicidal thoughts and behavior (suicidality) in patients with Huntington's disease. Balance the risks of depression and suicidality with the clinical need for treatment of chorea. Closely monitor patients for the emergence or worsening of depression, suicidality, or unusual changes in behavior. Inform patients, their caregivers, and families of the risk of depression and suicidality and instruct them to report behaviors of concern promptly to the treating physician. Exercise caution when treating patients with a history of depression or prior suicide attempts or ideation. AUSTEDO XR and AUSTEDO are contraindicated in patients who are suicidal, and in patients with untreated or inadequately treated depression.

Contraindications: AUSTEDO XR and AUSTEDO are contraindicated in patients with Huntington's disease who are suicidal, or have untreated or inadequately treated depression. AUSTEDO XR and AUSTEDO are also contraindicated in: patients with hepatic impairment; patients taking reserpine or within 20 days of discontinuing reserpine; patients taking monoamine oxidase inhibitors (MAOIs), or within 14 days of discontinuing MAOI therapy; and patients taking tetrabenazine or valbenazine.

Please see additional Important Safety Information throughout and [click here](http://www.AUSTEDOhcp.com) to visit www.AUSTEDOhcp.com to read/print the full Prescribing Information, including Boxed Warning, for AUSTEDO XR.



Important information about the AUSTEDO XR Pharmacy Order Template

Before accessing the AUSTEDO XR Pharmacy Order Template, the template must be published at the facility level by EHR Administrative Staff with Enterprise Management Console access, and either a “Clinical Setup Role” or a custom role with “Read/Add/Edit/Delete” access.

If help is needed to access the template, users can simply click the “?” in the top right corner to contact PointClickCare Customer Support.

For reference: titration schedule for AUSTEDO and AUSTEDO XR

TIP	AUSTEDO XR				AUSTEDO			
	Schedule	Dose to Admin.	Frequency	End Date Duration	Schedule	Dose to Admin.	Frequency	End Date Duration
For residents with TD that require a PA, tardive dyskinesia should be listed as the primary diagnosis. Abnormal Involuntary Movement Scale (AIMS) score may also be required.	Titration 1	12 mg	One time a day	7 Days	Titration 1	6 mg	Two times a day	7 Days
	Titration 2	18 mg	One time a day	7 Days	Titration 2	9 mg	Two times a day	7 Days
	Titration 3	24 mg	One time a day	7 Days	Titration 3	12 mg	Two times a day	7 Days
	Titration 4	30 mg	One time a day	7 Days	Titration 4	15 mg	Two times a day	7 Days
	Titration 5	36 mg	One time a day	7 Days	Titration 5	18 mg	Two times a day	7 Days
	Titration 6	42 mg	One time a day	7 Days	Titration 6	21 mg	Two times a day	7 Days
	Titration 7	48 mg	One time a day	Indefinite	Titration 7	24 mg	Two times a day	Indefinite

Billing Codes

ICD-10-CM Diagnosis Codes:

G24.01 tardive dyskinesia (TD) and G10 Huntington’s chorea

Please note that names mentioned in this guide are not real residents or providers.

A titration order template is also available for AUSTEDO. This guide will focus on ordering AUSTEDO XR for residents.

PA, prior authorization.

IMPORTANT SAFETY INFORMATION (Continued)

Clinical Worsening and Adverse Events in Patients with Huntington’s Disease: AUSTEDO XR and AUSTEDO may cause a worsening in mood, cognition, rigidity, and functional capacity. Prescribers should periodically re-evaluate the need for AUSTEDO XR or AUSTEDO in their patients by assessing the effect on chorea and possible adverse effects.

Please see additional Important Safety Information throughout and [click here](http://www.AUSTEDOhcp.com) to visit www.AUSTEDOhcp.com to read/print the full Prescribing Information, including Boxed Warning, for AUSTEDO XR.

Accessing the AUSTEDO XR Pharmacy Order Template

There are two options available for users to access the Pharmacy Order Template for AUSTEDO XR:

Option 1: New order entry—order template search

- 1 Once in a resident's chart, search for "Austedo XR" in the search bar to populate the AUSTEDO XR Pharmacy Order Template.

Option 2: New order entry—pharmacy order

- 2a Click on "New" and select "Pharmacy" to open a blank Pharmacy Order Template.
- 2b Navigate to the "Medication" field in the "Order Details" section. Search for "Austedo XR" and select the option under the "Template(s)" heading.

Order	Directions	Category	Status	Start Date	End Date	Revision Date
Acetaminophen Tablet 500 MG	Give 2 tablet by mouth every 6 hours as needed for P...	Pharmacy	Active	7/27/2017 17:30		5/10/2018
Colace Capsule 50 MG (Docusate Sodium)	Give 1 capsule by mouth in the afternoon for Constipa...	Pharmacy	Active	7/28/2017 16:00		7/27/2017
ARIPiprazole Tablet 2 MG	Give 1 tablet by mouth in the evening for depression	Pharmacy	Active	6/10/2019 18:00		6/9/2019
Digoxin Tablet 0.125 MG (Digoxin)	Give 1 tablet by mouth one time a day for A-Fib Apical...	Pharmacy	Active	3/26/2020 09:00		5/11/2022

TIP

Searching for "Aus" or "Austedo" may not populate all the dosage strengths for AUSTEDO XR. Be sure to search "Austedo XR" (include space before XR).

Order Details

Order Date: 8/11/2025 08 01

Order Category: Pharmacy

Communication Method: Phone Verbal Prescriber written Prescriber entered

Ordered By: [User] Last prescribed by: Dane Ashley
 (Current Primary Physician: Dane Ashley)

Search Library: Medispan Custom Show Inactive

2b Medication: *

Dispense as Written (DAW):

Order Type:

Route of Administration:

Scheduling Details

Add Schedule:

Source Details

Permanent Medication Source: Pharm
 Pharmacy: PHAR
 Pharmacy Notes:

Finalizing the AUSTEDO XR Pharmacy Order

TIP

If applying the titration template to order the AUSTEDO XR Therapy Pack (also known as the AUSTEDO XR Titration Kit):



Image shown is not actual 4-week Titration Kit.

- Navigate to the "Medication" field in the "Order Details" section, select "clear" after the order template has been selected, and then search "Austedo XR"
- Select "Therapy Pack," which will be the last option in your search results
- Navigate to the "Scheduling Details" section and delete Titrations 5, 6, and 7 by selecting the "x" at the top right corner of each button

Important note: Once the order is submitted, start a maintenance dose order for 36 mg/day. The start date should come immediately after the end date for Titration 4, and select "Indefinite" as the end date.

- 1 Finalizing titration schedule:** Number of titrations and "End Date" field will be automatically populated based on AUSTEDO XR Prescribing Information. To remove titrations, users can simply select the "x" at the top right corner of each button.
- 2 Ensuring "Facility Time Code" is entered:** Depending on each facility, the "Facility Time Code" field may be predefined and available for users to select using the drop-down menu. If a Facility Time Code is not predefined, users will need to enter it into the field.
- 3 Adding "Admin Notes":** The "Admin Notes" field is used to provide staff with additional information. Users can enter additional notes requested by the provider into this field.
- 4 Requesting the pharmacy apply the free trial voucher:** A note can be added to the "Pharmacy Notes" field for the pharmacy to apply the 30-day Free Trial Voucher against this initial order.* The voucher can be accessed by visiting AUSTEDOcardform.com.

An "Order Summary" will be generated for final confirmation. It summarizes a resident's full titration schedule for a complete 7-week series, as discussed on page 2.

*Certain restrictions apply. Terms and conditions on AUSTEDOcardform.com.

IMPORTANT SAFETY INFORMATION (Continued)

QTc Prolongation: AUSTEDO XR and AUSTEDO may prolong the QT interval, but the degree of QT prolongation is not clinically significant when AUSTEDO XR or AUSTEDO is administered within the recommended dosage range. AUSTEDO XR and AUSTEDO should be avoided in patients with congenital long QT syndrome and in patients with a history of cardiac arrhythmias.

Neuroleptic Malignant Syndrome (NMS), a potentially fatal symptom complex reported in association with drugs that reduce dopaminergic transmission, has been observed in patients receiving tetrabenazine. The risk may be increased by concomitant use of dopamine antagonists or antipsychotics. The management of NMS should include immediate discontinuation of AUSTEDO XR and AUSTEDO; intensive symptomatic treatment and medical monitoring; and treatment of any concomitant serious medical problems.

Please see additional Important Safety Information throughout and [click here](http://www.AUSTEDOhcp.com) to visit www.AUSTEDOhcp.com to read/print the full Prescribing Information, including Boxed Warning, for AUSTEDO XR.

Finalizing the AUSTEDO XR Pharmacy Order (Continued)

Before submitting the order for AUSTEDO XR, users should review and confirm the outstanding tasks listed below.

Order Details

Order Date: 8/11/2025 08 34

Order Category: Pharmacy *

Communication Method: Phone Verbal Prescriber written Prescriber entered *

Ordered By: [Search] * Last prescribed by: Dane Ashley
 (Current Primary Physician: Dane Ashley)

Medication: Austedo XR Oral Tablet Extended Release 24 Hour 12 MG clear *

Generic: Deutetrabenazine

Medication Class: PSYCHOTHERAPEUTIC AND NEUROLOGICAL AGENTS - MISC.

Dispense as Written (DAW):

Order Type: Psychoactive Medications - [MAR] *

Route of Administration: [Dropdown] show all *

Scheduling Details

Add Schedule: **Routine** PRN One Time Only Next Titration STAT

1 Titration 1 Titration 2 Titration 3 Titration 4 Titration 5 Titration 6 Titration 7

Dose or Admin Quantity: 12 mg show all *

Frequency: one time a day *

Schedule Type: Everyday *

2 Facility Time Code: [Dropdown] *

Start Date: 8/11/2025 08 17 *

End Date: Duration [Dropdown] 7 Day [Dropdown] 08/18/2025 08 16 *

Requires Reassessment

3 Admin Notes [Text Area] Supplementary Documentation SEs, SXs

Related Diagnoses: [Text Area] clear

For (Indications for Use): Involuntary Movements clear

Additional Directions: Do Not Crush, Chew, or Break Tablet. Developed in partnership with Teva using clinical guidelines. Use your own medical judgment.

Clinician Assisted Non-Clinical Staff Supervised Self-Administration


Administered By: Unsupervised Self-Administration *

Source Details

Permanent Medication Source: Pharmacy * Inventory on Hand

Pharmacy: [Name of Pharmacy] *

4 Pharmacy Notes: [Text Area]



Additional resources

[Click here](#) to contact your local LTC Account Manager or request a visit from an Access & Reimbursement Manager

[Click here](#) to explore tools and helpful videos for identifying, assessing, and treating TD in long-term care facilities

LTC, long-term care.

IMPORTANT SAFETY INFORMATION (Continued)

Akathisia, Agitation, and Restlessness: AUSTEDO XR and AUSTEDO may increase the risk of akathisia, agitation, and restlessness. The risk of akathisia may be increased by concomitant use of dopamine antagonists or antipsychotics. If a patient develops akathisia, the AUSTEDO XR or AUSTEDO dose should be reduced; some patients may require discontinuation of therapy.

Parkinsonism: AUSTEDO XR and AUSTEDO may cause parkinsonism in patients with Huntington's disease or tardive dyskinesia. Parkinsonism has also been observed with other VMAT2 inhibitors. The risk of parkinsonism may be increased by concomitant use of dopamine antagonists or antipsychotics. If a patient develops parkinsonism, the AUSTEDO XR or AUSTEDO dose should be reduced; some patients may require discontinuation of therapy.

Sedation and Somnolence: Sedation is a common dose-limiting adverse reaction of AUSTEDO XR and AUSTEDO. Patients should not perform activities requiring mental alertness, such as operating a motor vehicle or hazardous machinery, until they are on a maintenance dose of AUSTEDO XR or AUSTEDO and know how the drug affects them. Concomitant use of alcohol or other sedating drugs may have additive effects and worsen sedation and somnolence.

Hyperprolactinemia: Tetrabenazine elevates serum prolactin concentrations in humans. If there is a clinical suspicion of symptomatic hyperprolactinemia, appropriate laboratory testing should be done and consideration should be given to discontinuation of AUSTEDO XR and AUSTEDO.

Binding to Melanin-Containing Tissues: Deutetrabenazine or its metabolites bind to melanin-containing tissues and could accumulate in these tissues over time. Prescribers should be aware of the possibility of long-term ophthalmologic effects.

Common Adverse Reactions: The most common adverse reactions for AUSTEDO (>8% and greater than placebo) in a controlled clinical study in patients with Huntington's disease were somnolence, diarrhea, dry mouth, and fatigue. The most common adverse reactions for AUSTEDO (4% and greater than placebo) in controlled clinical studies in patients with tardive dyskinesia were nasopharyngitis and insomnia. Adverse reactions with AUSTEDO XR extended-release tablets are expected to be similar to AUSTEDO tablets.

Please see additional Important Safety Information throughout and [click here](#) to visit www.AUSTEDOhcp.com to read/print the full Prescribing Information, including Boxed Warning, for AUSTEDO XR.

REFERENCE: AUSTEDO XR® (deutetrabenazine) extended-release tablets and AUSTEDO® current Prescribing Information. Parsippany, NJ: Teva Neuroscience, Inc.

PointClickCare® is a registered trademark of *PointClickCare Technologies Inc.*

© 2025 Teva Neuroscience, Inc. AUS-48338 December 2025

